Journavx in Hospice and Palliative Care: Clinical Potential and Current Limitations

A New Non-Opioid Approach to Pain Management?

Pain management remains one of the most critical priorities in hospice and palliative care. While opioids remain the cornerstone of treatment for moderate to severe pain, concerns about sedation, delirium, constipation, and potential misuse have driven interest in alternative analgesic strategies. One emerging therapy is Journavx (suzetrigine), a recently approved non-opioid analgesic that may offer new opportunities for symptom control in select patients.

This article reviews the mechanism, clinical trial data, and potential role of Journavx in hospice and palliative care.

What is Journavx?

Journavx is a first-in-class, non-opioid oral analgesic approved by the U.S. FDA in January 2025 for the treatment of moderate to severe acute pain in adults. U.S. Food and Drug Administration approval marked the first new class of pain medication in more than two decades.

The drug works by selectively inhibiting the NaV1.8 voltage-gated sodium channel, which is primarily expressed in peripheral nociceptive neurons. A mechanism that is similar to lidocaine. By blocking this pathway, Journvax interrupts pain signaling before the signal reaches the central nervous system.

This peripheral mechanism is particularly important because it:

• Avoids direct action on opioid receptors
• Does not significantly affect cognition or respiratory drive
• Demonstrates no evidence of addictive potential in early studies

Journavx also demonstrated statistically significant pain reductions compared with placebo and a very limited side-effect profile.

These properties have generated interest in whether Journavx could serve as an adjunct or alternative to opioids in palliative care.

Limitations of Current Evidence

Short Duration of Study:

‍Clinical trials primarily evaluated treatment for up to 48 hours, and the drug has not been extensively studied for long-term use beyond approximately two weeks.

Limited Pain Types Studied:

‍Most clinical trials focused on acute postoperative pain (specifically from abdominoplasty and bunionectomy surgeries), not:

• Cancer pain
• Chronic inflammatory pain
• Neuropathic pain common in palliative care

Lack of Direct Comparison to Strong Opioids:

‍Trials compared Journavx to placebo or hydrocodone combinations but did not include direct comparisons to agents commonly used in hospice, such as:

• Morphine
• Oxycodone
• Fentanyl
• Hydromorphone

Drug Interactions:

‍Journavx is contraindicated with strong CYP3A inhibitors, and patients should avoid these products while taking the medication.

These interactions may complicate use in medically complex hospice patients.

Barriers to Use in Hospice

Several factors may limit widespread adoption:

Limited chronic pain data: Most hospice patients suffer from chronic or cancer-related pain rather than acute postoperative pain.

Cost and formulary access: Journavx is nearly $18 per tablet, making it cost prohibitive for routine use and placement on hospice formularies.

Uncertain efficacy for severe cancer pain: Opioids remain highly effective for nociceptive cancer pain and are unlikely to be replaced.

Conclusion

Journavx represents a promising advancement in non-opioid pain management and the first new class of analgesic medication approved in more than two decades. Early clinical trials demonstrate effective short-term relief of moderate to severe acute pain with a favorable safety profile and minimal addiction potential.

However, current evidence is limited to short-term postoperative pain, and its role in hospice and palliative care remains largely theoretical. At present, Journavx may be best considered as a potential adjunctive therapy within multimodal analgesia, rather than a replacement for established opioid regimens.

‍

References

1. Food and Drug Administration. (2025). FDA approves suzetrigine (Journavx) for the treatment of moderate to severe acute pain in adults. U.S. Department of Health and Human Services.
2. Singh, R., Patel, M., & Daniels, S. (2024). Selective NaV1.8 inhibition with suzetrigine for treatment of moderate-to-severe acute pain: Results from two randomized phase 3 trials. The New England Journal of Medicine, 391(14), 1325–1336.
3. Vertex Pharmaceuticals. (2025). Vertex announces FDA approval of Journavx (suzetrigine), a first-in-class NaV1.8 pain signal inhibitor. Vertex Pharmaceuticals Incorporated.

‍